Progenics, Bristol-Myers deal

Bristol-Myers will obtain exclusive rights to Progenics' GMK and MGV cancer vaccines, which

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE